Blood Signature of Pre-Heart Failure: A Microarrays Study
暂无分享,去创建一个
Michel Galinier | Romain Harmancey | Fatima Smih | Annie Turkieh | Philippe Rouet | J. Ferrières | A. Turkieh | P. Rouet | M. Galinier | A. Pathak | P. Massabuau | F. Smih | J. Iacovoni | R. Harmancey | O. Lairez | Atul Pathak | C. Delmas | C. Trouillet | Pierre Massabuau | François Koukoui | Franck Desmoulin | Olivier Lairez | F. Desmoulin | Jean Ferrieres | Matthieu Berry | Jason Iacovoni | Charlotte Trouillet | Clement Delmas | F. Koukoui | M. Berry
[1] P. Verdecchia,et al. Asymptomatic Left Ventricular Systolic Dysfunction in Essential Hypertension: Prevalence, Determinants, and Prognostic Value , 2005, Hypertension.
[2] J. Gardin,et al. Outcome of Congestive Heart Failure in Elderly Persons: Influence of Left Ventricular Systolic Function: The Cardiovascular Health Study , 2002, Annals of Internal Medicine.
[3] R. Kronmal,et al. The Cardiovascular Health Study: design and rationale. , 1991, Annals of epidemiology.
[4] E. J. Brown,et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. , 1992, The New England journal of medicine.
[5] G. Breithardt,et al. Real-time RT-PCR for gene expression profiling in blood of heart failure patients—A pilot study , 2004, Basic Research in Cardiology.
[6] D. Levy,et al. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.
[7] S. Yusuf,et al. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. , 1992, The New England journal of medicine.
[8] Daniel Levy,et al. The Epidemiology of Asymptomatic Left Ventricular Systolic Dysfunction: Implications for Screening , 2003, Annals of Internal Medicine.
[9] N. Sharpe,et al. Preventive treatment of asymptomatic left ventricular dysfunction following myocardial infarction. , 1990, European heart journal.
[10] N. Reichek,et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[11] J. Cleland,et al. Should we screen for asymptomatic left ventricular dysfunction to prevent heart failure? , 1998, European heart journal.
[12] Michel Galinier,et al. Uncomplicated human obesity is associated with a specific cardiac transcriptome: involvement of the Wnt pathway , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] Ash A. Alizadeh,et al. Individuality and variation in gene expression patterns in human blood , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[14] Jun Ma,et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. , 2006, The Journal of laboratory and clinical medicine.
[15] T. Marwick,et al. Screening for heart disease in diabetic subjects. , 2005, American heart journal.
[16] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[17] A Hofman,et al. Prevalence of heart failure and left ventricular dysfunction in the general population; The Rotterdam Study. , 1999, European heart journal.
[18] A. Maisel,et al. State-of-the-Art PaperNatriuretic Peptides , 2007 .
[19] Alan R. Dabney. ClaNC: point-and-click software for classifying microarrays to nearest centroids , 2006, Bioinform..
[20] R. Wachter,et al. Natriuretic peptides in the detection of preclinical diastolic or systolic dysfunction , 2010, Clinical Research in Cardiology.
[21] R. Lancashire,et al. Prevalence of left-ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: a population based study , 2001, The Lancet.
[22] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.
[23] Partha S. Vasisht. Computational Analysis of Microarray Data , 2003 .
[24] F. Crea,et al. Gene expression profiles in peripheral blood mononuclear cells of chronic heart failure patients. , 2009, Physiological genomics.
[25] Owen J. Marshall. PerlPrimer: cross-platform, graphical primer design for standard, bisulphite and real-time PCR , 2004, Bioinform..
[26] M. Davies,et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). , 2007, European heart journal.
[27] Hugh Tunstall-Pedoe,et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population , 1997, The Lancet.
[28] Perry M. Elliott,et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 , 2010, European journal of heart failure.
[29] A. Hoes,et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. , 2005, European heart journal.
[30] M. Gheorghiade,et al. The role of N-terminal PRO-brain natriuretic peptide and echocardiography for screening asymptomatic left ventricular dysfunction in a population at high risk for heart failure. The PROBE-HF study. , 2009, Journal of cardiac failure.
[31] Pedro Lozano. Natriuretic peptides. , 2020, The Journal of the Arkansas Medical Society.
[32] R. Doll,et al. The Epidemiology of Cancer , 1980, Cancer.
[33] C. Emanueli,et al. Cardiovascular actions of neurotrophins. , 2009, Physiological reviews.
[34] S. Frøland,et al. Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure. , 2002, Cardiovascular research.
[35] Roland Eils,et al. Reliability of gene expression ratios for cDNA microarrays in multiconditional experiments with a reference design. , 2004, Nucleic acids research.
[36] G. Breithardt,et al. Real-time RT-PCR for gene expression profiling in blood of heart failure patients-a pilot study: gene expression in blood of heart failure patients. , 2004, Basic research in cardiology.
[37] Richard Simon,et al. Bias in error estimation when using cross-validation for model selection , 2006, BMC Bioinformatics.
[38] M. Esler,et al. Reduced myocardial nerve growth factor expression in human and experimental heart failure. , 2000, Circulation research.
[39] D. Mozaffarian,et al. Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.